Global /United States /Healthcare /Biotechnology /JBIO

Jade Biosciences, Inc.

JBIO

• NASDAQ: JBIO • Delayed

22.32USD -16%

As of 13 June 2026, Jade Biosciences, Inc. has a market cap of $1.1B USD, ranking #10166 globally and #2098 in the United States. It ranks #894 in the Healthcare sector, and #166 in the Biotechnology industry.

Global Rank

10166

Country Rank

2098

Sector Rank

894

Industry Rank

166

Key Stats

Market Cap

$1.1BUSD

Enterprise Value

$836.83MUSD

EBITDA (TTM)

-$113.52MUSD

Net Income (TTM)

-$100.14MUSD

PB Ratio

3.9

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Tom Frohlich open_in_new

Employees

Founded

2024

Website

jadebiosciences.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-16%	-2.3%	68%	44%	130%	46%	121%	-97%	-98%

News

JBIO Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	JBIO Jade Biosciences Inc ISIN: US0080642061 Shares Out.: Shares Outstanding: 60.86M¹ Shares Float: 50.08M² TV: TradingView: NASDAQ: JBIO SA: Stock Analysis: NASDAQ: JBIO YF: Yahoo Finance: JBIO GF: Google Finance: NASDAQ: JBIO NQ: NASDAQ: JBIO BA: Barron's: JBIO MS: Morningstar: XNAS: JBIO	22.32 USD	TV: TradingView: NASDAQ: JBIO SA: Stock Analysis: NASDAQ: JBIO YF: Yahoo Finance: JBIO GF: Google Finance: NASDAQ: JBIO NQ: NASDAQ: JBIO BA: Barron's: JBIO MS: Morningstar: XNAS: JBIO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 16K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 14K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 2K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 2K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 2K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 2K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 4K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 4K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 4K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 4K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 2K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 2K%	-	Germany

chevron_leftBack